Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia
出版年份 2013 全文链接
标题
Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia
作者
关键词
-
出版物
LEUKEMIA
Volume 27, Issue 9, Pages 1803-1812
出版商
Springer Nature
发表日期
2013-06-12
DOI
10.1038/leu.2013.173
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Genomic impact of transient low-dose decitabine treatment on primary AML cells
- (2013) J. M. Klco et al. BLOOD
- Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes
- (2013) Yun-Gyoo Lee et al. BRITISH JOURNAL OF HAEMATOLOGY
- Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
- (2013) U Platzbecker et al. LEUKEMIA
- Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation
- (2013) T Schroeder et al. LEUKEMIA
- In Vivo Quantification of Active Decitabine-Triphosphate Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia
- (2012) Hongyan Wang et al. AAPS Journal
- Allogeneic Hematopoietic Cell Transplantation in Patients Age 60-70 Years with De Novo High-Risk Myelodysplastic Syndrome or Secondary Acute Myelogenous Leukemia: Comparison with Patients Lacking Donors Who Received Azacitidine
- (2012) Uwe Platzbecker et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia
- (2012) A. Quintas-Cardama et al. BLOOD
- Block of red blood cell maturation in acute erythroid leukemia
- (2012) S. Blum et al. BLOOD
- Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes
- (2012) M. A. Sekeres et al. BLOOD
- The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience
- (2012) M. Lamarque et al. BLOOD
- Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia
- (2012) W. Blum et al. BLOOD
- Revised International Prognostic Scoring System for Myelodysplastic Syndromes
- (2012) P. L. Greenberg et al. BLOOD
- Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study
- (2012) Robert S. Jansen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains
- (2012) J. J. Trowbridge et al. GENES & DEVELOPMENT
- Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia
- (2012) D. A. Pollyea et al. HAEMATOLOGICA
- Phase II Trial of Vorinostat With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myelogenous Leukemia or Myelodysplastic Syndrome
- (2012) Guillermo Garcia-Manero et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies
- (2012) Gandhi Damaj et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- (2012) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- What Is Better for Older Patients With Acute Myeloid Leukemia?
- (2012) Felicetto Ferrara et al. JOURNAL OF CLINICAL ONCOLOGY
- Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML
- (2012) S Ettou et al. LEUKEMIA
- A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission
- (2012) Y Boumber et al. LEUKEMIA
- Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML
- (2011) J. M. Scandura et al. BLOOD
- Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes
- (2011) Lewis R. Silverman et al. CANCER
- Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
- (2011) Guillermo Garcia-Manero et al. JOURNAL OF CLINICAL ONCOLOGY
- Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
- (2011) Michael Lübbert et al. JOURNAL OF CLINICAL ONCOLOGY
- Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
- (2011) U Platzbecker et al. LEUKEMIA
- DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia
- (2011) K H Metzeler et al. LEUKEMIA
- Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
- (2011) R Itzykson et al. LEUKEMIA
- Cancer epigenetics reaches mainstream oncology
- (2011) Manuel Rodríguez-Paredes et al. NATURE MEDICINE
- The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome
- (2010) T. Prebet et al. BLOOD
- In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia
- (2010) J. Choi et al. BLOOD
- Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
- (2010) R. Itzykson et al. BLOOD
- Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia
- (2010) O. Goodyear et al. BLOOD
- Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome
- (2010) Marcos de Lima et al. CANCER
- DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia
- (2010) Maria E. Figueroa et al. CANCER CELL
- Rac GTPases play multiple roles in erythropoiesis
- (2010) P. Ji et al. HAEMATOLOGICA
- Single Cycle of Arsenic Trioxide–Based Consolidation Chemotherapy Spares Anthracycline Exposure in the Primary Management of Acute Promyelocytic Leukemia
- (2010) Steven D. Gore et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of Complete Remission and Responses Less Than Complete Remission on Survival in Acute Myeloid Leukemia: A Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study
- (2010) Roland B. Walter et al. JOURNAL OF CLINICAL ONCOLOGY
- Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes
- (2010) M Y Follo et al. LEUKEMIA
- A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines
- (2010) Paul W. Hollenbach et al. PLoS One
- Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
- (2010) W. Blum et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting
- (2009) L. I. Sanchez-Abarca et al. BLOOD
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
- (2009) H. Dohner et al. BLOOD
- Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies
- (2009) T. E. Fandy et al. BLOOD
- MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation
- (2009) M. E. Figueroa et al. BLOOD
- Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes
- (2009) Roger M. Lyons et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial
- (2009) David P. Steensma et al. JOURNAL OF CLINICAL ONCOLOGY
- DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes
- (2009) Lanlan Shen et al. JOURNAL OF CLINICAL ONCOLOGY
- Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
- (2009) Pierre Fenaux et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
- The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells
- (2009) C Flotho et al. LEUKEMIA
- DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction
- (2009) Ann-Marie Bröske et al. NATURE GENETICS
- Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS
- (2009) M. Y. Follo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study
- (2008) L. Ades et al. BLOOD
- Aberrant DNA methylation is a dominant mechanism in MDS progression to AML
- (2008) Y. Jiang et al. BLOOD
- DNA methylation inhibition increases T cell KIR expression through effects on both promoter methylation and transcription factors
- (2008) Ying Liu et al. CLINICAL IMMUNOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started